Madam Speaker, I heard the hon. member make a very strong case for national pharmacare, which I fully support. He spoke about the need and about the affordability.
However, as a member of the health committee, I can say that affordability is a critical piece of it, but it is not enough. There is complexity, and we have heard from many witnesses that there is great complexity. Will there be provincial or national formularies? Who will decide the drugs that will go on those formularies? As we heard from so many constitutional, science, and consumer groups—evidence-based groups—it is not just about affordability; it is about how to do it right. How do we make sure, if we launch this final very important step, that all Canadians are covered for pharmaceutical prescriptions?
Why would we not wait? Let the committee address those complexities. It will have recommendations and thoughts on this issue. Let the full report come to the committee, and let the committee finish its work with the PBO. No one has actually examined the PBO yet on this report. To go ahead would be premature.
How would you address these complexities?